Bridging the Gap: Efficacy of Low-Dose Emicizumab in Haemophilia A With or Without Inhibitors
{{output}}
Introduction: Emicizumab has proven to be a turning point in the management of patients with Haemophilia A (HA). In resource-limited settings, data on low-dose emicizumab prophylaxis (LDEP) in HA patients are emerging. ... ...
